Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
Taiwan · Delayed Price · Currency is TWD 134.00
+2.50 (1.90%)
May 29, 2026, 1:30 PM CST
TPEX:6712 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,030 | 1,018 | 933.81 | 758.39 | 627.51 | 438.84 | |
Revenue Growth (YoY) | 8.61% | 8.96% | 23.13% | 20.86% | 42.99% | 521.61% |
Cost of Revenue | 282.92 | 296.18 | 273.77 | 273.64 | 212.96 | 193.36 |
Gross Profit | 747.15 | 721.33 | 660.04 | 484.75 | 414.56 | 245.48 |
Selling, General & Admin | 48.83 | 44.23 | 47.18 | 47.91 | 40.07 | 45.14 |
Research & Development | 237.04 | 238.16 | 147.22 | 99.11 | 90.69 | 84.14 |
Other Operating Expenses | 0.02 | - | 44.38 | - | - | - |
Operating Expenses | 285.82 | 282.33 | 238.85 | 147.02 | 130.76 | 129.28 |
Operating Income | 461.33 | 439 | 421.19 | 337.73 | 283.8 | 116.2 |
Interest Expense | -0.87 | -0.92 | -0.13 | -0.2 | -0.51 | -0.62 |
Interest & Investment Income | 32.03 | 27.97 | 10.89 | 14.18 | 9.88 | 6 |
Earnings From Equity Investments | -5.84 | -9.25 | 52.09 | - | - | - |
Currency Exchange Gain (Loss) | - | - | - | 21.76 | -30.72 | - |
Other Non Operating Income (Expenses) | 46.82 | 28.8 | 23.31 | 7.52 | 7.35 | 4.27 |
EBT Excluding Unusual Items | 533.46 | 485.61 | 507.35 | 380.99 | 269.79 | 125.85 |
Gain (Loss) on Sale of Investments | 38.73 | 38.73 | -46.68 | 241.86 | -5.7 | 261.05 |
Gain (Loss) on Sale of Assets | - | - | - | - | -0 | 11.33 |
Asset Writedown | - | - | - | - | - | -1.94 |
Other Unusual Items | 0 | 0 | 0.08 | 0.17 | 0.01 | 0.52 |
Pretax Income | 572.19 | 524.33 | 460.74 | 623.01 | 264.1 | 396.82 |
Income Tax Expense | 99.16 | 94.9 | 93.49 | 83.62 | 63.39 | 27.22 |
Net Income | 473.03 | 429.43 | 367.25 | 539.4 | 200.71 | 369.6 |
Net Income to Common | 473.03 | 429.43 | 367.25 | 539.4 | 200.71 | 369.6 |
Net Income Growth | 9.09% | 16.93% | -31.91% | 168.74% | -45.69% | - |
Shares Outstanding (Basic) | 104 | 92 | 93 | 94 | 95 | 95 |
Shares Outstanding (Diluted) | 104 | 92 | 93 | 95 | 96 | 96 |
Shares Change (YoY) | 11.31% | -0.92% | -1.68% | -1.01% | 0.15% | 11.01% |
EPS (Basic) | 4.56 | 4.65 | 3.94 | 5.71 | 2.11 | 3.90 |
EPS (Diluted) | 4.56 | 4.65 | 3.94 | 5.69 | 2.09 | 3.87 |
EPS Growth | -2.04% | 17.92% | -30.71% | 171.69% | -45.83% | - |
Free Cash Flow | 548.47 | 535.07 | 435.49 | 415.92 | 316.02 | 133.7 |
Free Cash Flow Per Share | 5.28 | 5.79 | 4.67 | 4.39 | 3.30 | 1.40 |
Dividend Per Share | 3.333 | 3.333 | 4.329 | 4.723 | 1.431 | 3.253 |
Dividend Growth | -24.79% | -23.00% | -8.33% | 229.90% | -56.00% | - |
Gross Margin | 72.53% | 70.89% | 70.68% | 63.92% | 66.06% | 55.94% |
Operating Margin | 44.79% | 43.14% | 45.11% | 44.53% | 45.23% | 26.48% |
Profit Margin | 45.92% | 42.20% | 39.33% | 71.12% | 31.99% | 84.22% |
Free Cash Flow Margin | 53.25% | 52.59% | 46.63% | 54.84% | 50.36% | 30.47% |
EBITDA | 472.62 | 450.78 | 440.28 | 357.69 | 307.28 | 141.47 |
EBITDA Margin | 45.88% | 44.30% | 47.15% | 47.16% | 48.97% | 32.24% |
D&A For EBITDA | 11.29 | 11.79 | 19.09 | 19.96 | 23.48 | 25.27 |
EBIT | 461.33 | 439 | 421.19 | 337.73 | 283.8 | 116.2 |
EBIT Margin | 44.79% | 43.14% | 45.11% | 44.53% | 45.23% | 26.48% |
Effective Tax Rate | 17.33% | 18.10% | 20.29% | 13.42% | 24.00% | 6.86% |